{
    "nct_id": "NCT04180215",
    "official_title": "A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "All patients:\n\n* Metastatic central nervous system disease, and/or carcinomatous meningitis.\n* Any serious or uncontrolled medical disorder that, in the opinion of the Investigator, may increase the risk associated with study participation / treatment administration.\n* Concurrent malignancy that is clinically significant or requires active intervention, unless protocol-defined criteria are met.\n* Active, known or suspected, autoimmune or inflammatory disorders requiring immunosuppressive therapy.\n* Has a life expectancy of less than 3 months.\n* Any toxicities attributed to systemic prior anticancer therapy o that have not resolved to Grade 1 or baseline prior to the first administration of study drug, unless protocol-defined criteria is met.\n* Not meeting the protocol-specified washout periods for prohibited medications.\n* Prior anaphylactic reaction to or known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).\n* Positive hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody, indicating acute or chronic infection.\n* Known history of acquired immunodeficiency syndrome.\n\nFor patients in Groups E or F and certain backfill cohorts:\n\n* History of severe hypersensitivity reaction to or other contraindication to receiving pembrolizumab.\n* History of/Presently having non-infectious pneumonitis requiring treatment.\n* Was discontinued due to a Grade 3 or higher immune-related AE (irAE) after receiving prior therapy with check point inhibitors.\n\nImaging Sub-Study (for specific participants at Memorial Sloan Kettering Cancer Center only):\n\n* Having splenic disorders or prior splenectomy, and can compromise protocol objectives per Investigator and/or Sponsor.\n* Meeting requirements of exclusion criteria for Treatment Group 3",
    "miscellaneous_criteria": "Inclusion Criteria\n\nAll Patients:\n\n* Documentation of confirmed HPV 16+ cancer via genotype testing.\n* ≥ 1 measurable lesion by imaging for tumor response following RECIST\n* ECOG performance status of 0 to 1.\n* Prior curative radiation therapy and prior focal palliative completed per protocol-specified wash-out windows.\n* Screening laboratory values must meet protocol-specified criteria.\n* Able to provide tumor tissue following last treatment, unless otherwise agreed.\n\nTreatment Group E or Group F:\n\n* Documentation of confirmed head and neck squamous cell carcinoma.\n* Eligible to receive pembrolizumab, per standard of care and product label.\n* Group E: this group includes first line / 1L patients who have not yet received treatment in the metastatic/recurrent setting.\n* Group F: Tumor progression or recurrence on standard of care therapy, including ≥1 systemic therapy.\n\nImaging Sub-Study (for specific participants at Memorial Sloan Kettering Cancer Center only):\n\n* Meeting requirements of inclusion criteria for Treatment Group 1 or Group 3.\n* At least 1 non-irradiated measurable lesion documented through imaging."
}